learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
3 / 3 resultslearn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
learn Stem Cell Factor
Research
5 / 1000+ resultsresearch Pharmacotherapy for Keloids and Hypertrophic Scars
Combination pharmacotherapy is generally more effective for treating keloids and hypertrophic scars.
research Proteolysis-Targeting Chimera (PROTAC): Current Applications And Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Drug Eruptions
Any medication can cause skin reactions, some due to allergies and others due to dosage or genetic factors.
research Understanding, Recognizing, and Managing Toxicities of Targeted Anticancer Therapies
Targeted anticancer therapies can cause severe side effects similar to traditional chemotherapy, but with different types.
research Compilation of a Comprehensive Gene Panel for Systematic Assessment of Genes That Govern an Individual’s Drug Responses
Researchers found that most genes affecting drug responses are not fully covered by commercial SNP chips, suggesting the need for more comprehensive tools to optimize drug selection based on genetics.
Community Join
5 / 52 resultscommunity The likely cost of HMI-115, when it comes out
A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.
community All Drugs in Clinical Trials in 2023
12 companies having drugs or therapies in clinical trials during 2023, with various molecules and phases of trial; the probability that some may fail; and progress being made in the field.
community Residents of Victoria, Australia, sign up for a monoclonal antibody clinical trial – potential cure
A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community UPDATE: The theory that explains everything. Please help me make this big!
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.